CMPX

Business Context and Reporting Period

Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Compass is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company targets the relationship between angiogenesis, the immune system, and tumor growth. It has no products approved for commercial sale and has never generated revenue from product sales.

Key Financial Metrics

Liquidity: As of December 31, 2025, the company held $209 million in cash, cash equivalents, and marketable securities. Management estimates these resources will fund operating expenses and capital expenditures into 2028.

Material Changes vs. Prior Period

• Revenue: Licensing revenue decreased by $0.85 million to zero in 2025. The 2024 revenue consisted of a milestone payment from Elpiscience for completing a Phase 1 trial in China.
• Operating Expenses: Total operating expenses increased by $15.4 million (26.7%) to $72.8 million.
  • R&D: Increased by $13.6 million, primarily driven by a $14.2 million increase in manufacturing expenses for tovecimig and CTX-10726.
  • G&A: Increased by $1.7 million due to commercialization expenses and advisory fees.
• Financing Activity: In August 2025, the company completed an underwritten public offering, raising net proceeds of approximately $129.3 million. This significantly bolstered cash reserves compared to the prior year.

Guidance, Outlook, and Risks

Outlook and Pipeline Progress

• Tovecimig (Lead Candidate): Met its primary endpoint in a randomized Phase 2/3 trial for biliary tract cancer (BTC) with an Overall Response Rate (ORR) of 17.1% vs. 5.3% for control (p=0.031). Top-line data for Progression-Free Survival (PFS) and Overall Survival (OS) is expected in April 2026. A Phase 2 monotherapy study in colorectal cancer (CRC) showed a 5% ORR in heavily pre-treated patients.
• CTX-471: Phase 1 data identified a potential biomarker (NCAM/CD56). A Phase 2 basket study using this biomarker is expected to initiate in mid-2026.
• CTX-8371: Phase 1 dose escalation showed deep responses in NSCLC, TNBC, and Hodgkin lymphoma. Cohort expansions are ongoing.
• CTX-10726: Received FDA clearance for IND in early 2026; Phase 1 dose escalation study initiated.

Management Commentary

Management expects to continue incurring significant operating losses for the foreseeable future. The company anticipates expenses will increase substantially as it advances clinical development and prepares for potential commercialization.

Risks and Contingencies

• Capital Requirements: The company requires substantial additional financing to pursue business objectives. Failure to obtain capital could force delays or termination of product development.
• Clinical Uncertainty: Clinical development involves lengthy, expensive processes with uncertain outcomes. Positive early results may not predict future success.
• Regulatory Approval: No products are approved. Regulatory approval processes are unpredictable, and failure to obtain approval would materially harm the business.
• Competition: The oncology market is highly competitive with larger, better-funded companies.

Investor Verification Checklist

• Cash Runway: Verify the $209 million cash balance and the management estimate of funding operations into 2028 against current burn rates.
• Tovecimig Data Readout: Monitor the April 2026 release of PFS and OS data from the pivotal Phase 2/3 BTC trial, which is critical for regulatory filing.
• Manufacturing Costs: Review the $14.2 million increase in manufacturing expenses to ensure supply chain stability for clinical trials.
• Dilution Risk: Assess the impact of the recent $129.3 million equity raise and potential future financing needs on shareholder dilution.
• Patent Expiry: Confirm the timeline for patent expirations (starting 2033 for tovecimig) relative to expected commercialization dates.